Neuroartropatía de Charcot
DOI:
https://doi.org/10.47196/diab.v48i2.209Palabras clave:
neuroartropatía, patogénesis, diagnóstico, tratamientoResumen
La neuroartropatía de Charcot (NC) es un síndrome asociado con polineuropatía diabética (PND), caracterizado por fragmentación y destrucción ósea y articular que puede conducir a severas deformidades e incluso la amputación.Es una artropatía relativamente dolorosa, progresiva, degenerativa, de una o múltiples articulaciones, causada por un déficit neurológico subyacente.
En 1868 Jean-Martín Charcot describió, por primera vez, esta enfermedad en los pacientes con tabes dorsal como la “artropatía de los atáxicos”.El primer caso reportado en la literatura de neuroartropatía en un paciente con diabetes data del año 1936.La diabetes es en la actualidad la causa más frecuente de neuroartropatía.
El objetivo de esta revisión es proporcionar una visión general de la neuroartropatía de Charcot en términos de patogénesis, clasificación, presentación clínica, diagnóstico y tratamiento, con especial énfasis en los nuevos conceptos sobre patogenia y tratamiento.
Citas
Boulton A. J. M. The diabetic foot. An update. Foot Ankle Surg. 14:120-124, 2008.
Shojaie A, Esmaelzadeh M, Larijani B. Assessment and treatment of diabetic foot ulcer. Int. J. Clin. Pract. 61:1931-1938, 2007.
Crawford F, Mccowan C, Dimitrov BD, Woodburn J, Wylie GH, Booth E. The risk of foot ulceration in people with diabetes screened in community settings: findings from a cohort study. Q. J. Med. 1-8, 2010.
Bruges J, Márquez G, Macedo G, Ramos F, Valero K, Calvagno M, Schinca N, Gayoso R, Jubiz Y. Guías ALAD de Pie diabético XVIII (N°2):73-86, 2010.
International Consensus Group on the Diabetic Foot and Practical Guidelines on the Management and the Prevention of the Diabetic Foot, Versions 1999, 2003, 2007. (www.idf.org/bookshop).
Boulton AJM, Armstrong D, Albert S y col. ADA-AACE Task Force. Diabetes Care 31:1679-1685, 2008.
Botek G, Andreson M, Taylor R. Charcot neuroarthropathy: an often overlooked complication of diabetes. Cleveland Clinic Journal of Medicine 77:593-599, 2010.
Viñes G. Neuroartropatía o articulación de Charcot. Revista Nefrología Argentina 8:120-121, 2010.
Van Bon A. C. Charcot Neuro-Osteoarthropathy. Global Perspective on Diabetic Foot Ulcerations, 14:271-278, 2011.
Young MJ, Marshall A, Adams JE, Selby PL, Boulton AJ. Osteopenia, neurological dysfunction, and the development of Charcot neuroarthropathy. Diabetes Care 18:34-8, 1995.
Tan AL, Greenstein A, Jarrett SR, Mc Gonagle D. Acute neuropathic joint disease: medical emergancy? Diabetes Care 28:2962-4, 2005.
Rogers LC, Frykberg RG, Armstrong DG, Boulton AJM, Edmonds M. The Charcot foot in diabetes. Diabetes Care 34:2123-9, 2011.
Neuroartropatía de Charcot. http://www.diabetes.org.ar/docs/7-charcot.pdf.
Pappalardo J, Fitzgerald R. Utilization of advanced modalities in the management of diabetic Charcot neuroarthropathy. Am. J. Med. 6:1114-1120, 2010.
Gouveri E, Papanas N. Charcot osteoarthropathy in diabetes: a brief review with an emphasis on clinical practice. World J. Diabetes 2:59-65, 2011.
Mabilleau G, Edmonds ME. Role of neuropathy on fracture healing in Charcot neuro-osteoarthropathy. J. Musculoskelet Neuronal Interact. 10:84-91, 2010.
Witzke KA, Vinik AI, Grant LM y col. Loss of RAGE defense: a cause of Charcot neuroarthropathy? Diabetes Care 34:1617-1621, 2011.
Schoots IG, Slim FJ, Busch-Westbroek TE, Maas M. Neuro-osteoarthropathy of the foot-radiologist: friend or foe? Semin. Musculoskelet Radiol. 14:365-376, 2010.
Trepman E, Nihal A, Pinzur MS. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int. 26:46-63, 2005.
Petrova NL, Edmonds ME. Charcot neuro-osteoarthropathycurrent standards. Diabetes Metab. Res. Rev 24:S58-S61, 2008.
Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J. Diabetes Complications 23:409-426, 2009.
Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 45:1085-1096, 2002.
Jeffcoate W, Lima J, Nobrega L.The Charcot foot. Diabet. Med. 17:253-258, 2000.
Armstrong DG, Todd WF, Lavely LA, Harkless LB, Bushman TR. The natural history of acute Charcot’s arthropathy in a diabetic foot specialty clinic. Diabet. Med. 14:357-363, 1997.
Griffith J, Davies AM, Close CF, Nattrass M. Organized chaos? Computed tomographic evaluation of the neuropathic diabetic foot. Br. J. Radiol. 68:27-33, 1995.
Van der Ven A, Chapman CB, Bowker JH. Charcot neuroarthropathy of the foot and ankle. J. Am. Acad. Orthop. Surg. 17:562-571, 2009.
Petrova NL, Foster AV, Edmonds ME. Difference in presentation of charcot osteoarthropathy in type 1 compared with type 2 diabetes. Diabetes Care 27:1235-1236, 2004.
Larson SA, Burns PR. The pathogenesis of Charcot neuroarthropathy: current concepts. Diabet Foot Ankle 3:122-36, 2012.
Mabilleau G, Petrova N, Edmonds M, Sabokbar A. Increased osteoclastic activity in acute Charcot’s osteoarthropathy: the role of receptor activator of nuclear factor-kappa B ligand. Diabetologia 51:1035-40, 2008.
La Fontaine J, Shibuya N, Sampson HW, Valderrama P. Trabecular quality and cellular characteristics of normal, diabetic, and Charcot bone. J. Foot Ankle Surg. 50:648-53, 2011.
Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 366:2058-2061, 2005.
Rostom S, Bahiri R, Mahfoud-Filali S, Hajjaj-Hassouni N. Neurogenic osteoarthropathy in leprosy. Clin. Rheumatol. 26:2153-5, 2007.
Chantelau E, Onvlee GJ. Charcot foot in diabetes: farewell to the neurotrophic theory. Horm. Metab. Res. 38:361-7, 2006.
Jeffcoate W. Charcot neuro-osteoarthropathy. Diabetes Metab. Res. Rev. 24:S62-5, 2008.
Jones KB, Mollano AV, Morcuende JA. Bone and brain: a review of neural, hormonal, and musculoskeletal connections. Iowa Orthop J 24:123-32, 2004.
Tesfaye S, Stevens LK, Stephenson JM, Fuller JH. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. Diabetologia 39:1377-84, 1996.
Chantelau E, Richter A, Schmidt-Grigoriadis P, Scherbaum WA. The diabetic Charcot foot: MRI discloses bone stres injury as trigger mechanism of neuroarthropathy. Exp. Clin. Endocrinol. Diabetes 114:118-23, 2006.
Jeffcoate WJ. Abnormalities of vasomotor regulation in the pathogenesis of the acute Charcot foot of diabetes mellitus. Int. J. Low Extrem. Wounds 4:133-7, 2005.
Ndip A, Jude EB, Whitehouse R, Prescott M, Boulton AJ. Charcot neuroarthrtopathy triggered by osteomyelitis and/or surgery. Diabet. Med. 25:1469-72, 2008.
Aragón Sánchez J, Lázaro Martínez JL, Hernández Herrero MJ. Triggering mechanisms of neuroarthropathy following conservative surgery for osteomyelitis. Diabet Med. 27:844-7, 2010.
Rangel ÉB, Sá JR, Gomes SA, Carvalho AB, Melaragno CS. Charcot neuroarthropathy after simultaneous pancreas_kidney transplant. Transplantation 94:642-5, 2012.
Jeffcoate W. The causes of the Charcot syndrome. Clin. Podiatr. Med. Surg. 25:29-42, 2008.
Chisholm KA, Gilchrist JM. The Charcot joint: a modern neurologic perspective. J Clin. Neuromusc. Dis. 13:1-13, 2011.
Slater RA, Ramot Y, Buchs A. The diabetic Charcot foot. Med. Assoc. J. 6:280-3, 2004.
Gökhan K, Olgar B, Mehmet G, Tahir Ö. An overview of the Charcot foot pathophysiology. Diabetic Foot & Ankle 4: 211-17, 2013.
Papanas N, Maltezos E. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabet Foot Ankle. 21:4-10, 2013.
Baumhauer JF, O’Keefe RJ, Schon LC, Pinzur MS. Cytokine induced osteoclastic bone resorption in Charcot arthropathy: an immunohistochemical study. Foot Ankle Int 227:797-800, 2006.
Uccioli L, Sinistro A, Almerighi C, Ciaprini C. Proinflammatory modulation of the surface and cytokine phenotype of monocytes in patients with acute Charcot foot. Diabetes Care 33:350-5, 2010.
Wang L, Shi X, Zhao R, Halloran BP, Clark DJ. Calcitoningene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation,osteoclastogenesis and bone resorption. Bone 46:1369-79, 2010.
Ndip A, Williams A, Jude EB, Serracino-Inglott F. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic charcot neuroarthropathy. Diabetes 60:2187-96, 2011.
Jeffcoate WJ. Theories concerning the pathogenesis of the acute Charcot foot suggest future therapy. Curr. Diab. Rep. 5:430-5, 2005.
Lam J, Abu-Amer Y, Nelson CA, Fremont DH, Ross FP, Teitelbaum SL. Tumor necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolisis.
Ann. Rheum. Dis. 62:ii82–ii83, 2002.
. Xu J, Wu HF, Ang ES, Yip K, Woloszyn M, Zheng MH, Tan RX. NF-k b modulators in osteolytic bone diseases. Cytokine Growth Factor Rev. 20:7-17, 2009.
Pitocco D, Ruotolo V, Caputo S, Mancini L, Collina CM. Sixmonth treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 28:1214-5, 2005.
Stevens MJ, Edmonds ME, Foster AV, Watkins PJ. Selective neuropathy and preserved vascular responses in the diabetic Charcot foot. Diabetologia. 35:148-54, 1992.
Imai S, Matsusue Y. Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Microsc. Res. Tech. 58:61-9, 2002.
Offley SC, Guo TZ, Wei T, Clark JD, Vogel H, Lindsey DP. Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J. Bone Miner. 20:257-67, 2005.
Akopian A, Demulder A, Ouriaghli F, Corazza F, Fondu P, Bergmann P. Effects of CGRP on human osteoclast-like cell formation: a possible connection with the bone loss in neurological disorders? Peptides 21:559-64, 2000.
La Fontaine J, Harkless LB, Sylvia VL, Carnes D, Heim-Hall J, Jude E. Levels of endothelial nitric oxide synthase and calcitonin gene-related peptide in the Charcot foot: a pilot study. J. Foot Ankle Surg. 47:424-429, 2008.
Blakytny R, Spraul M, Jude EB. Review: the diabetic bone: a cellular and molecular perspective. Int. J. Low Extrem. Wounds 10:16-32, 2011.
Tan SD, Bakker AD, Semeins CM, Kuijpers-Jagtman AM, Klein-Nulend J. Inhibition of osteocyte apoptosis by fluid flow is mediated by nitric oxide. Biochem Biophys Res Comun 369:1150-4, 2008.
Nilforoushan D, Gramoun A, Glogauer M, Manolson MF. Nitric oxide enhances osteoclastogenesis possibly by mediating cell fusion. Nitric. Oxide 21:27-36, 2009.
Baker N, Green A, Krishnan S, Rayman G. Microvascular and C-fiber function in diabetic Charcot neuroarthropathy and diabetic peripheral neuropathy. Diabetes Care 30:3077-9, 2007.
Shapiro SA, Stansberry KB, Hill MA, Meyer MD. Normal blood flow response and vasomotion in the diabetic Charcot foot. J. Diabetes Complications 12:147-53, 1998.
Christensen TM, Simonsen L, Holstein PE, Svendsen OL, Bülow J. Sympathetic neuropathy in diabetes mellitus patients does not elicit Charcot osteoarthropathy. J Diabetes Complications 25:320-4, 2011.
Schaper NC, Huijberts M, Pickwell K. Neurovascular control and neurogenic inflammation in diabetes. Diabetes Metab. Res. 24:S40-4, 2008.
Christensen TM, Bülow J, Simonsen L, Holstein PE, Svendsen OL. Bone mineral density in diabetes mellitus patients with and without a Charcot foot. Clin Physiol. Funct. Imaging 30:130-4, 2010.
Petrova NL, Foster AV, Edmonds ME. Calcaneal bone mineral density in patients with Charcot neuropathic osteoarthropathy: differences between type 1 and type 2 diabetes. Diabet Med. 22:756-61, 2005.
Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NF-kB and MCP-1 expression in human aortic endothelial cells.J. Clin. Endocrinol. Metab. 86:450-3, 2001.
Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J. Bone Miner. Res. 1996;11:931-937.
Levin ME, Boisseau VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N. Engl. J. Med. 294:241-245, 1976.
Kume S, Kato S, Yamagishi S y col. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J. Bone Miner Res. 20:1647-1658, 2005.
Alikhani M, Alikhani Z, Boyd C y col. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40:345-353, 2007.
Yaturu S. Diabetes and skeletal health. J. Diabetes 1:246-254, 2009.
Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch. Physiol. Biochem.113:154-161, 2007.
McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress.BMC Cell Biol. 2:16, 2001.
Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen in bone strength. Osteoporos Int. 17:319-36, 2006.
Kim JG, Kim JH, Kim JY, Ku SY, Jee BC. Association between osteoprotegerin (OPG), receptor activator of nuclear factorkappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14:913-8, 2007.
Pitocco D, Zelano G, Gioffrè G, Di Stasio E, Zaccardi F. Association between osteoprotegerin G1181C and T245G polymorphisms and diabetic Charcot neuroarthropathy: a case-control study. Diabetes Care 32:1694-7, 2009.
Korzon_Burakowska A, Jako´bkiewicz-Banecka J, Fiedosiuk A, Petrova N. Osteoprotegerin gene polymorphism in diabetic Charcot neuroarthropathy. Diabet. Med. 29:771-5, 2012.
Asuncion J, Valcarcel P, Poggio D. Neuroartropatía de Charcot. Pie Diabético Digital 12:6-18, 2011.
Hordon LD, Goldberg DL, Nathan DM, Romain PL. Diabetic neuropathic arthropathy. Up to Date. 2010.
Stapleton JJ, Belezyk R, Zgonis T. Revisional Charcot neuroarthropathy of the foot and ankle. J. Am. Acad. Orthop. Surg. 26:127-39, 2009.
Gómez Vargas E, Pérez Hernández J. Características clínicas y radiológicas de 15 pacientes con osteoartropatía diabética. Revista de la Asociación Latinoamericana de Diabetes. XIII-Nº1, 2005.
Batista F. Estadiamiento y tratamiento del pie de Charcot. Pie Diabético Digital 6:16-21, 2009.
Batista F, Monteiro AC. Tratamento Cirúrgico da Neuroartropatía de Charcot: Apresentação de técnicas e resultados preliminares. Diabetes Clínica 7:358-366, 2005.
Giurini JM, Chrzan JS, Gibbons GW, Habershaw GM. Charcot’s disease in diabetic patients. Correct diagnosis can prevent progressive deformity. Postgrad Med. 89:163-169, 1991.
MS. Pinzur. Current Concepts Review: Charcot arthropathy of the foot and ankle. Foot Ankle Int. 28:952-959, 2007.
JW Brodsky. The diabetic foot. In Coughlin MJ, Mann RA, Saltzman CL. Eds. Surgery of the Foot and Ankle. Philadelphia: Mosby Elsevier, 2007: 1333.
Petrova NL, Moniz C, Elias DA, Buxton-Thomas M, Bates M, Edmonds ME. Is there a systemic inflammatory response in the acute charcot foot? Diabetes Care 30:997-998, 2007.
Akinci B, Yener S, Yesil S, Yapar N, Kucukyavas Y, Bayrakta. Acute phase reactants predict the risk of amputation in diabetic foot infection. J. Am. Podiatr. Med. Assoc. 101:1-6, 2011.
Robinson AHN, Pasapula C, Rodsky JW. Surgical aspects of the diabetic foot. J Bone Joint Surg Br. 91:1-7, 2009.
Sella EJ, Barrette C. Staging of Charcot neuroarthropathy along the medial column of the foot in the diabetic patient. J. Foot Ankle Surg. 38:34-40, 1999.
Gold RH, Tong DJ, Crim JR, Seeger LL. Imaging the diabetic foot. Skeletal Radiol. 24:563-571, 1995.
Keidar Z, Militianu D, Melamed E, Bar-Shalom R, Israel O. The diabetic foot: initial experience with 18F-FDG PET/CT.J Nucl. Med. 46:444-449, 2005.
Hopfner S, Krolak C, Kessler S, Tiling R. Preoperative imaging of Charcot neuroarthropathy. Does the additional application of 18F-FDG-PET make sense? Nuklearmedizin 45:15-20, 2005.
S. Heiba, D. Kolker, B. Mocherla, K. Kapoor, M. Jiang, H. The optimized evaluation of diabetic foot infection by dual isotope SPECT/CT imaging protocol. Foot Ankle Surg. 49:529-536, 2010.
Herbst SA, Jones KB, Saltzman CL. Pattern of diabetic neuropathic arthropathy associated with the peripheral bone mineral density. J. Bone Joint Surg. Br. 86:378-383, 2004.
Chantelau E. The perils of procrastination: effects of early vs. delayed detection and treatment of incipient Charcot fracture. Diabet. Med. 22:1707-1712, 2005.
Tan PL, Teh J. MRI of the diabetic foot: differentiation of infection from neuropathic change. Br. J. Radiol. 80:939-948, 2007.
Bem R, Jirkovska Q, Fejifarova V y col. Itranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomised controlled trial. Diabetes Care 29:1392-1394, 2006.
Frykberg, R. G, & Eneroth, M. Principles of conservative management. In: The Diabetic Charcot Foot: principles and management. Frykberg RG, Ed. Brooklandville, MD, Data Trace Publishing Company 93-116, 2010.
Armstrong DG, Lavery LA, Wu S, Boulton AJ. Evaluation of removable and irremovable cast walkers in the healing of diabetic foot wounds: a randomized controlled trial. Diabetes Care 28:551-554, 2005.
Armstrong DG, Short B, Espensen EH, Abu-Rumman PL, Nixon BP, Boulton AJ. Technique for fabrication of an “instant total-contact cast” for treatment of neuropathic diabetic foot ulcers. J Am. Podiatr.Med. Assoc. 92:405-408, 2002.
Viade J, Perez J. C.Neuropatía de Charcot. Pie Diabético Digital 13:2-9, 2011.
Assal M, Stern R. Realignment and extended fusion with use of a medial column screw for midfoot deformities secondary to diabetic neuropathy. J. Bone Joint Surg. Am. 91:812-20, 2009.
Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, Donohoe M, Foster AV, Edmonds ME, Boulton AJ. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 44:2032-2037, 2001.
Selby PL, Young MJ, Boulton AJ. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet. Med 11:28-31, 1994.
Anderson JJ, Woelffer KE, Holtzman JJ, Jacobs AM. Bisphosphonates for the treatment of Charcot neuroarthropathy. J. Foot Ankle Surg. 43:285-289, 2004.
Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS. Osteoblasts play key role in the mechanisms of action of strontium ranelate. British Journal of Pharmacology 2009; 157: 1291-1300.
Boulton AJ, Jeffcoate WJ, Jones TL, Ulbrecht JS. International collaborative research on Charcot’s disease. Lancet 373:105-106, 2009.
Denosumab. Sociedad Argentina de Endocrinología y Metabolismo. www.saem.org.ar/denosumab.asp.
Pinzur MS. Surgical management: history and general principles. In The Diabetic Charcot Foot: Principles and Management. Data Trace Publishing Company 165-188, 2010.
Sammarco VJ. Superconstructs in the treatment of Charcot foot deformity: plantar plating, locked plating, and axial screw fixation. Foot Ankle Clin. 14:393-407, 2009.
Holstein P, Lohmann M, Bitsch M, Jorgensen B. Achilles tendon lengthening, the panacea for plantar forefoot ulceration? Diabetes Metab. Res. 20:S37-40, 2004.
Simon SR, Tejwani SG, Wilson DL, Santner TJ, Denniston NL. Arthrodesis as an early alternative to nonoperative management of charcot arthropathy of the diabetic foot. J. Bone Joint Surg. Am. 82:939-950, 2000.
Stefansky SA, Rosenblum BI. The Charcot foot: a clinical challenge. Int. J. Low Extrem. Wounds 4:183-187, 2005.
Pinzur MS. Neutral ring fixation for high-risk nonplantigrade Charcot midfoot deformity. Foot Ankle Int 28:961-966, 2007.
Conway JD. Charcot salvage of the foot and ankle using external fixation. Foot Ankle Clin. 13:157-173, 2008.
Jani MM, Ricci WM, Borrelli J Jr, Barrett SE, Johnson JE. A protocol for treatment of unstable ankle fracturing using transarticular fixation in patients with diabetes mellitus and loss of protective sensibility. Foot Ankle Int. 24:838-44, 2003.
Mittlmeier T, Klaue K, Haar P, Beck M. Should one consider primary surgical reconstruction in Charcot arthropathy of the feet? Clin. Orthop. Relat. Rev. 468:1002-1011, 2010.
Fabrin J, Larsen K, Holstein PE. Arthrodesis with external fixation in the unstable or misaligned Charcot ankle in patients with diabetes mellitus. Int. J Low Extrem. Wounds 6:102-107, 2007.
Wukich DK, Belczyk RJ, Burns PR, Frykberg RG. Complications encountered with circular ring fixation in persons with diabetes mellitus. Foot Ankle Int. 29:994-1000, 2008.
Bevilacqua NJ, Rogers LC. Surgical management of Charcot midfoot deformities. Clin. Podiatr. Med. Surg. 25:81-94, 2008.
Ayoub MA. Ankle fractures in diabetic neuropathic arthropathy: can tibiotalar arthrodesis salvage the limb?J Bone Joint Surg. Br. 90:906-914, 2008.
Dalla Paola L, Volpe A, Varotto D y col. Use of a retrograde nail for ankle arthrodesis in Charcot neuroarthropathy: a limb salvage procedure. Foot Ankle Int. 28:967-970, 2007.
Caravaggi C, Cimmino M, Caruso S, Dalla Noce S. Intramedullary compressive nail fixation for the treatment of severe Charcot deformity of the ankle and rear foot. J. Foot Ankle Surg. 45:20-24, 2006.
Pinzur MS, Noonan T. Ankle arthrodesis with a retrograde femoral nail for Charcot ankle arthropathy. Foot Ankle Int. 26:545-549, 2005.
Grant WP, Jerlin EA, Pietrzak WS, Tam HS. The utilization of autologous growth factors for the facilitation of fusion in complex neuropathic fractures in the diabetic population. Clin. Podiatr. Med. Surg. 22:561-84, 2005.
Gandhi A, Bibbo C, Pinzur M, Lin SS. The role of platelet-rich plasma in foot and ankle surgery. Foot Ankle Clin. 10:621-37, 2005.
Liporace FA, Bibbo C, Azad V, Koerner J, Lin SS. Bioadjuvants for complex ankle and hindfoot reconstruction. Foot Ankle Clin. 12:75-106, 2007.
Pinzur MS. Use of platelet-rich concentrate and bone marrow aspirate in high-risk patients with Charcot arthropathy of the foot. Foot Ankle Int. 30:124-7, 2009.
Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Am. 84:1032-44, 2002.
Schuberth JM, Di Domenico LA, Mendicino RW. The utility and effectiveness of bone morphogenetic protein in foot and ankle surgery. J. Foot Ankle Surg. 48:309-14, 2009.
Guerkov HH, Lohmann CH, Liu Y, Dean DD, Simon BJ, Heckman JD, Schwartz Z, Boyan BD. Pulsed electromagnetic fields increase growth factor release by nonunion cells. Clin. Orthop. Relat. Res. 384:265-79, 2001.
Brighton CT, Wang W, Seldes R, Zhang G, Pollack SR. Signal transduction in electrically stimulated bone cells. J. Bone Joint Surg. Am. 83:1514-23, 2001.
Hockenbury RT, Gruttadauria M, McKinney I. Use of implantable bone growth stimulation in Charcot ankle arthrodesis. Foot Ankle Int. 28:971-6, 2007.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
